Journal of New Developments in Chemistry

Mohammed El-Gamal, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea; 
University of Science and Technology (UST), Daejeon, Republic of Korea
Editorial Board

Mohammed El-Gamal

Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea;  University of Science and Technology (UST), Daejeon, Republic of Korea · Korea, Republic Of

Editorial leadership for Journal of New Developments in Chemistry ISSN 2377-2549

Research interests

  • Medicinal Chemistry Drug Design
  • Synthesis Biological Screening Of Novel Therapeutics Pharmacokinetics &Amp; Pharmacodynamics Molecular Modeling

Biography

  • Mohammed I. El-Gamal, Ph.D. got his B.Sc. degree in pharmaceutical Sciences at the Faculty of Pharmacy, University of Mansoura, Egypt in 2003 with "Excellent with honor" grade, first achiever. 
  • Then he received his M.Sc. degree in medicinal chemistry from the same college. 
  • He got his Ph.D. degree in medicinal chemistry in August 2012 from Korea University of Science and Technology, Korea Institute of Science and Technology (KIST), Republic of Korea. 
  • After that, he worked as a star postdoctoral fellow at KIST and assistant professor of medicinal chemistry at the Faculty of Pharmacy, University of Mansoura, Egypt. 
  • Mohammed I. El-Gamal, Ph.D. is the author of more than 50 publications in highly reputed journals. 
  • He got 3 patents, and presented more than 36 posters and 8 oral presentations in many international conferences in The Republic of Korea, United Arab Emirates, USA, Japan, The Netherlands, and Austria. 
  • He has peer-review more than 50 articles. 
  • And he has been an editorial board member in more than 13 international journals. He has been also a member of the Asian Council of Science Editors (ACSE). 
  • Mohammed I. El-Gamal, Ph.D. and his group have developed a new more efficient prodrug of Olmesartan (antihypertensive agent) which has been marketed in the Republic of Korea. 
  • And he is interested in anticancer, anti-inflammatory, and antimicrobial drug development.

Considering JNDC for your work?

This journal is guided by Mohammed El-Gamal (Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea;  University of Science and Technology (UST), Daejeon, Republic of Korea) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.

Start your submission

Menu